BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38612726)

  • 21. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
    Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BMI1 is a therapeutic target in recurrent medulloblastoma.
    Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
    Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.
    Ambrosio S; Amente S; Saccà CD; Capasso M; Calogero RA; Lania L; Majello B
    Oncotarget; 2017 Jan; 8(3):3854-3869. PubMed ID: 27894074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
    Jiang Q; Stachelscheid J; Bloehdorn J; Pacholewska A; Aszyk C; Grotenhuijs F; Müller T; Onder O; Wagle P; Herling CD; Kleppe M; Wang Z; Coombes KR; Robrecht S; Dalvi PS; Plosnita B; Mayer P; Abruzzo LV; Altmüller J; Gathof B; Persigehl T; Fischer K; Jebaraj B; Rienhoff HY; Ecker R; Zhao Y; Bruns CJ; Stilgenbauer S; Elenitoba-Johnson K; Hallek M; Schweiger MR; Odenthal M; Vasyutina E; Herling M
    Blood; 2023 Jul; 142(1):44-61. PubMed ID: 37023372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
    Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
    Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion.
    Li Y; Wan X; Wei Y; Liu X; Lai W; Zhang L; Jin J; Wu C; Shao Q; Shao G; Lin Q
    Oncol Rep; 2016 Jun; 35(6):3586-92. PubMed ID: 27109588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
    Venkata PP; Jayamohan S; He Y; Alejo S; Johnson JD; Palacios BE; Pratap UP; Chen Y; Liu Z; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Weintraub ST; Palakurthi S; Valente PT; Tekmal RR; Kost ER; Vadlamudi RK; Sareddy GR
    Cancer Lett; 2023 Oct; 575():216383. PubMed ID: 37714256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic deletion of
    Ramírez-Ramírez R; Gutiérrez-Angulo M; Peregrina-Sandoval J; Moreno-Ortiz JM; Franco-Topete RA; Cerda-Camacho FJ; Ayala-Madrigal ML
    J Clin Pathol; 2020 Feb; 73(2):107-111. PubMed ID: 31471467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of miR-137 in Children with Medulloblastoma and its Regulatory Effect on Tumor Progression.
    Ji W; Zhe X; Li L; Cheng Y; Zhao X; Liang P; Long C; Zhou J
    Neuromolecular Med; 2022 Jun; 24(2):215-223. PubMed ID: 34409560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
    Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
    J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma.
    Leiendecker L; Jung PS; Krecioch I; Neumann T; Schleiffer A; Mechtler K; Wiesner T; Obenauf AC
    EMBO Mol Med; 2020 Nov; 12(11):e12525. PubMed ID: 33026191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition.
    Lin T; Ponn A; Hu X; Law BK; Lu J
    Oncogene; 2010 Sep; 29(35):4896-904. PubMed ID: 20562920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
    Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
    Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic modification mechanism of histone demethylase KDM1A in regulating cardiomyocyte apoptosis after myocardial ischemia-reperfusion injury.
    He L; Wang Y; Luo J
    PeerJ; 2022; 10():e13823. PubMed ID: 35959481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
    Song Y; Zhang H; Yang X; Shi Y; Yu B
    Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells.
    Hino S; Kohrogi K; Nakao M
    Cancer Sci; 2016 Sep; 107(9):1187-92. PubMed ID: 27375009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
    Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
    Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.
    Althoff K; Beckers A; Odersky A; Mestdagh P; Köster J; Bray IM; Bryan K; Vandesompele J; Speleman F; Stallings RL; Schramm A; Eggert A; Sprüssel A; Schulte JH
    Int J Cancer; 2013 Sep; 133(5):1064-73. PubMed ID: 23400681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of human trophoblast syncytialization by histone demethylase LSD1.
    Milano-Foster J; Ray S; Home P; Ganguly A; Bhattacharya B; Bajpai S; Pal A; Mason CW; Paul S
    J Biol Chem; 2019 Nov; 294(46):17301-17313. PubMed ID: 31591264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers.
    Lee DY; Salahuddin T; Iqbal J
    Curr Oncol; 2023 Feb; 30(2):2127-2143. PubMed ID: 36826125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.